To assess the benefits and harms of transjugular intrahepatic portosystemic shunts in patients with liver cirrhosis and hepatorenal syndrome versus sham or no intervention or versus conventional therapies (combination of octreotide, midodrine, terlipressin, norepinephrine, albumin, and paracentesis) to other therapies (pharmacologic therapy).